VHL MUTATION (Q28444948)

From Wikidata

Jump to navigation Jump to search

genetic variant

MUTATION

Language	Label	Description	Also known as
English	VHL MUTATION	genetic variant	MUTATION

Statements

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/variants/160

Loss Of Function Variant

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/variants/160

human chromosome 3

genomic assembly

Genome assembly GRCh37

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/variants/160

10182692

genomic assembly

Genome assembly GRCh37

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/variants/160

10193904

genomic assembly

Genome assembly GRCh37

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/variants/160

biological variant of

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/variants/160

positive therapeutic predictor for

medical condition treated

renal cell carcinoma

statement disputed by

The role of aberrant VHL/HIF pathway elements in predicting clinical outcome to pazopanib therapy in patients with metastatic clear-cell renal cell carcinoma.

determination method or standard

CIViC evidence level B

CIViC 2-star trust rating

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/evidence/1672

The role of aberrant VHL/HIF pathway elements in predicting clinical outcome to pazopanib therapy in patients with metastatic clear-cell renal cell carcinoma.

determination method or standard

CIViC evidence level B

CIViC 4-star trust rating

medical condition treated

renal cell carcinoma

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/evidence/5323

Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma

negative therapeutic predictor for

anti vascular endothelial growth factor therapy

determination method or standard

CIViC evidence level B

CIViC 4-star trust rating

medical condition treated

renal cell carcinoma

1 reference

1 August 2019

https://civic.genome.wustl.edu/links/evidence/4832

Prognostic and predictive value of VHL gene alteration in renal cell carcinoma: a meta-analysis and review

positive prognostic predictor for

renal clear cell carcinoma

determination method or standard

CIViC evidence level B

CIViC 4-star trust rating

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/evidence/418

Low CAIX expression and absence of VHL gene mutation are associated with tumor aggressiveness and poor survival of clear cell renal cell carcinoma

Identifiers

CIViC variant ID

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/variants/160

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q28444948&oldid=2014801104"